KIF27: A Potential Drug Target for Neurological Disorders (G55582)

Target Name: KIF27

NCBI ID: G55582

KIF27

KIF27: A Potential Drug Target for Neurological Disorders

KIF27 (RP11-575L7.3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related peptidases (KAPs) family and is involved in the regulation of inflammation and cell signaling. KIF27 has been identified as a potential drug target and is the focus of ongoing research at the laboratory of Professor X.

The KAPs family is a group of transmembrane proteins that belong to the superfamily of proteases. These proteins are characterized by the presence of a catalytic center that consists of a tryptophan residue, a histidine residue, and a lysine residue. KAPs are involved in the regulation of various cellular processes, including inflammation, cell signaling, and cell death.

KIF27 is a 27 kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related peptidases (KAPs) family and is involved in the regulation of inflammation and cell signaling. KIF27 has been identified as a potential drug target and is the focus of ongoing research at the laboratory of Professor X.

KIF27 is involved in the regulation of several cellular processes, including inflammation, cell signaling, and cell death. It is a key regulator of the pro-inflammatory response and is involved in the regulation of inflammation and tissue repair. KIF27 has been shown to play a role in the regulation of neuroinflammation, and is Therefore, it is a promising drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

KIF27 is also involved in the regulation of cell signaling, including the regulation of cell growth, differentiation, and survival. It is a key regulator of the TGF-β pathway, which is involved in the regulation of cellular growth and differentiation. KIF27 has been shown to play a role in the regulation of TGF-β signaling and is Therefore, a potential drug target for the treatment of various cancers, including breast cancer and colon cancer.

KIF27 is also involved in the regulation of cell death, including apoptosis. It is a key regulator of the cell death signaling pathway and is involved in the regulation of cell survival and death. KIF27 has been shown to play a role in the regulation of cell death signaling and is Therefore, a potential drug target for the treatment of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

KIF27 is a 27 kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related peptidases (KAPs) family and is involved in the regulation of inflammation and cell signaling. KIF27 has been identified as a potential drug target and is the focus of ongoing research at the laboratory of Professor X.

Protein Name: Kinesin Family Member 27

Functions: Plays an essential role in motile ciliogenesis

The "KIF27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets